General：Ozefloxacin is a quinolone antibacterial drug developed by a Spanish company. It was approved for market by the US FDA in 2017 and is the third non fluoroquinolone antibacterial drug approved globally, following narfloxacin and garfloxacin. The mechanism of action of Ozefloxacin is to inhibit bacterial DNA replicase, DNA gyrase A, and topoisomerase IV. Used in clinical trials to treat skin and soft tissue infections., Strong bactericidal activity. Suitable for treating pustules caused by infection with Staphylococcus aureus or Streptococcus pyogenes in patients aged two months and above.